PL3290051T3 - Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi - Google Patents

Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi

Info

Publication number
PL3290051T3
PL3290051T3 PL16786583T PL16786583T PL3290051T3 PL 3290051 T3 PL3290051 T3 PL 3290051T3 PL 16786583 T PL16786583 T PL 16786583T PL 16786583 T PL16786583 T PL 16786583T PL 3290051 T3 PL3290051 T3 PL 3290051T3
Authority
PL
Poland
Prior art keywords
cancer
prevention
treatment
pharmaceutical composition
pharmaceutical
Prior art date
Application number
PL16786583T
Other languages
English (en)
Inventor
Akira Kurihara
Hyongi Chon
Takayuki Fujita
Fumiyoshi Okano
Original Assignee
Toray Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Inc. filed Critical Toray Industries, Inc.
Publication of PL3290051T3 publication Critical patent/PL3290051T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C07K4/12—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16786583T 2015-04-30 2016-04-28 Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi PL3290051T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015093640 2015-04-30
PCT/JP2016/063420 WO2016175307A1 (ja) 2015-04-30 2016-04-28 癌の治療及び／又は予防用医薬組成物
EP16786583.1A EP3290051B1 (en) 2015-04-30 2016-04-28 Pharmaceutical composition for treating and/or preventing cancer

Publications (1)

Publication Number Publication Date
PL3290051T3 true PL3290051T3 (pl) 2020-04-30

Family

ID=57198482

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16786583T PL3290051T3 (pl) 2015-04-30 2016-04-28 Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi

Country Status (15)

Country Link
US (1) US11129893B2 (pl)
EP (1) EP3290051B1 (pl)
JP (1) JP6862828B2 (pl)
KR (1) KR102729994B1 (pl)
CN (1) CN107530426A (pl)
AU (1) AU2016255255B2 (pl)
BR (1) BR112017022390A2 (pl)
DK (1) DK3290051T3 (pl)
ES (1) ES2762979T3 (pl)
HU (1) HUE047272T2 (pl)
MX (1) MX380750B (pl)
PL (1) PL3290051T3 (pl)
PT (1) PT3290051T (pl)
RU (1) RU2714205C2 (pl)
WO (1) WO2016175307A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112424358B (zh) 2018-06-26 2025-07-01 协和麒麟株式会社 与细胞粘附分子3结合的抗体
CA3104997A1 (en) * 2018-06-26 2020-01-02 Kyowa Kirin Co., Ltd. Antibody binding to chondroitin sulfate proteoglycan 5
CN111073889B (zh) * 2019-12-20 2023-07-28 中国人民解放军第四军医大学 人cspg5基因的用途及相关产品

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
JPH09194502A (ja) 1995-11-13 1997-07-29 Seikagaku Kogyo Co Ltd 新規コンドロイチン硫酸プロテオグリカン、そのコア蛋白質、それをコードするｄｎａおよびそれに対する抗体
JP4315257B2 (ja) 1995-11-13 2009-08-19 生化学工業株式会社 新規コンドロイチン硫酸プロテオグリカン、そのコア蛋白質、それをコードするｄｎａおよびそれに対する抗体
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
TWI390034B (zh) 2006-04-06 2013-03-21 Kyowa Hakko Kirin Co Ltd Novel anti-CD98 antibody
CN101245386A (zh) * 2008-03-26 2008-08-20 中南大学 用于多种肿瘤抑瘤基因检测的cDNA芯片
PL2305300T3 (pl) 2008-07-10 2016-09-30 Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi
DK2322221T3 (da) * 2008-08-05 2014-09-01 Toray Industries Farmaceutisk sammensætning til behandling og forebyggelse af cancer
CA2767442A1 (en) 2009-07-08 2011-01-13 Actgen Inc. Antibody having anti-cancer activity
JP2013013327A (ja) * 2009-10-29 2013-01-24 Actgen Inc Ｍａｎｓｃ１蛋白質に結合し、抗癌活性を有する抗体
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof

Also Published As

Publication number Publication date
HUE047272T2 (hu) 2020-04-28
AU2016255255B2 (en) 2021-07-22
BR112017022390A2 (pt) 2018-10-23
CA2983232A1 (en) 2016-11-03
WO2016175307A1 (ja) 2016-11-03
AU2016255255A1 (en) 2017-11-02
MX380750B (es) 2025-03-12
JP6862828B2 (ja) 2021-04-21
CN107530426A (zh) 2018-01-02
KR102729994B1 (ko) 2024-11-14
RU2714205C2 (ru) 2020-02-13
PT3290051T (pt) 2020-01-07
ES2762979T3 (es) 2020-05-26
US11129893B2 (en) 2021-09-28
RU2017135005A (ru) 2019-04-08
KR20170141660A (ko) 2017-12-26
EP3290051A4 (en) 2018-12-05
EP3290051A1 (en) 2018-03-07
MX2017013480A (es) 2017-12-07
US20180085453A1 (en) 2018-03-29
EP3290051B1 (en) 2019-10-23
JPWO2016175307A1 (ja) 2018-02-22
RU2017135005A3 (pl) 2019-09-04
DK3290051T3 (da) 2020-01-06

Similar Documents

Publication Publication Date Title
IL258955B2 (en) Cancer treatment preparations and methods
IL255333A0 (en) Vaccines for the treatment and prevention of cancer
HUE042081T2 (hu) Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
PL3377516T3 (pl) Kompozycja do leczenia nowotworu
IL254133A0 (en) Combination of a pd-1 antagonist and eribulin for treating cancer
PT3277270T (pt) Composições e métodos de tratamento de anemia
PL3189074T3 (pl) Kompozycje oraz sposoby leczenia i zapobiegania zapaleniom
PL3200815T3 (pl) Sposoby i kompozycje do leczenia nowotworu
IL254842B (en) Therapeutic preparations and methods for use in cancer treatment
HUE067973T2 (hu) Eljárások és készítmények rák kezelésére
PL3397967T3 (pl) Kompozycje i sposoby do wykrywania i leczenia raka przełyku
IL263697A (en) Compounds, compositions and methods for prevention and/or treatment of cancer
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
IL263793A (en) Compounds and preparations for the treatment of cancer
IL280587B (en) Fluorocitidine derivatives and their preparations for use in cancer treatment
ZA201802376B (en) Compositions and methods for treatment of homocystinuria
IL257336B (en) Pharmaceutical compounds and preparations for the prevention or treatment of parasitic diseases
HUE051563T2 (hu) Gyógyszerkészítmény rák megelõzésére vagy kezelésére
GB201511799D0 (en) Composition and methods of treatment
PT3290051T (pt) Composição farmacêutica para o tratamento e/ou prevenção de cancro
PL3459542T3 (pl) Zastosowanie związku karbaminianu do zapobiegania lub leczenia neuralgii nerwu trójdzielnego
EP3661953A4 (en) CANCER TREATMENT METHODS AND COMPOSITIONS
IL257689B (en) Pharmaceutical preparations and methods for treating diseases related to lack of oxygen
PL3319638T3 (pl) Kompozycja zawierająca cyneol do leczenia chorób nowotworowych i/lub raków
ITUB20160141A1 (it) Composizione per la prevenzione ed il trattamento di cefalee primarie